OBJECTIVES: Melanoma is a significant cause of morbidity and mortality worldwide and incidence is increasing. Survival after treatment is inversely related to the thickness of the tumour at diagnosis. Population screening has the potential to reduce mortality but there is no conclusive evidence of benefit. Such evidence can come best from a randomised trial. Here we describe the design of a community based randomised trial of a population screening programme for melanoma in Queensland, Australia and early results of the first phase of the trial. METHODS:A total of 44 communities (aggregate population 560 000 adults aged 30 years or more) will be randomised to receive either a community based screening programme for 3 years or normal practice. The screening programme promotes thorough skin self examination and whole body skin examination by a doctor and provides open access skin cancer screening clinics. In its first phase, the trial is underway in nine intervention and nine control communities. The primary outcome measure is mortality from melanoma during 15 years of follow up. RESULTS: The first phase of the trial has shown the feasibility of implementing a population skin screening programme including regular skin cancer screening clinics, and has shown the strong support of communities and doctors for the programme. There has been a significant 2.5-fold increase in participation in screening in the intervention communities in this first phase after the first 12 months of the trial and no significant increase in participation in screening in control communities during this period. CONCLUSIONS: The design of a community based randomised trial of screening for melanoma has been successfully peer reviewed and the intervention has been shown to be feasible in practice. This randomised trial may be one of the last opportunities to develop the evidence required for public health recommendations for population screening for melanoma.
RCT Entities:
OBJECTIVES:Melanoma is a significant cause of morbidity and mortality worldwide and incidence is increasing. Survival after treatment is inversely related to the thickness of the tumour at diagnosis. Population screening has the potential to reduce mortality but there is no conclusive evidence of benefit. Such evidence can come best from a randomised trial. Here we describe the design of a community based randomised trial of a population screening programme for melanoma in Queensland, Australia and early results of the first phase of the trial. METHODS: A total of 44 communities (aggregate population 560 000 adults aged 30 years or more) will be randomised to receive either a community based screening programme for 3 years or normal practice. The screening programme promotes thorough skin self examination and whole body skin examination by a doctor and provides open access skin cancer screening clinics. In its first phase, the trial is underway in nine intervention and nine control communities. The primary outcome measure is mortality from melanoma during 15 years of follow up. RESULTS: The first phase of the trial has shown the feasibility of implementing a population skin screening programme including regular skin cancer screening clinics, and has shown the strong support of communities and doctors for the programme. There has been a significant 2.5-fold increase in participation in screening in the intervention communities in this first phase after the first 12 months of the trial and no significant increase in participation in screening in control communities during this period. CONCLUSIONS: The design of a community based randomised trial of screening for melanoma has been successfully peer reviewed and the intervention has been shown to be feasible in practice. This randomised trial may be one of the last opportunities to develop the evidence required for public health recommendations for population screening for melanoma.
Authors: Mary K Tripp; Meg Watson; Sophie J Balk; Susan M Swetter; Jeffrey E Gershenwald Journal: CA Cancer J Clin Date: 2016-05-27 Impact factor: 508.702
Authors: Jeremy R Etzkorn; Rajiv P Parikh; Suroosh S Marzban; Kimberly Law; Ashley H Davis; Bhupendra Rawal; Michael J Schell; Vernon K Sondak; Jane L Messina; Lois E Rendina; Jonathan S Zager; Mary H Lien Journal: Cancer Control Date: 2013-10 Impact factor: 3.302
Authors: Clara Curiel-Lewandrowski; Caroline C Kim; Susan M Swetter; Suephy C Chen; Allan C Halpern; John M Kirkwood; Sancy A Leachman; Ashfaq A Marghoob; Michael E Ming; James M Grichnik Journal: J Invest Dermatol Date: 2012-02-16 Impact factor: 8.551
Authors: Jacqueline M Goulart; Elizabeth A Quigley; Stephen Dusza; Sarah T Jewell; Gwen Alexander; Maryam M Asgari; Melody J Eide; Suzanne W Fletcher; Alan C Geller; Ashfaq A Marghoob; Martin A Weinstock; Allan C Halpern Journal: J Gen Intern Med Date: 2011-04-07 Impact factor: 5.128
Authors: Loraine A Escobedo; Ashley Crew; Ariana Eginli; David Peng; Michael R Cousineau; Myles Cockburn Journal: Health Place Date: 2017-04-06 Impact factor: 4.078